Obe-cel in Adult ALL - The FELIX Study

The FELIX study is our phase 2 clinical trial designed to evaluate our obe-cel product in patients with relapsed/refractory adult B-cell acute lymphoblastic leukemia. At an interim analysis completed in Q4 2022, the study met its primary endpoint of overall response rate.

The FELIX study has recruited patients in locations across the US, UK and Spain and although active, is not recruiting patients. For further information on this study please follow this link NCT04404660 or to speak to a doctor conducting this study in your area please contact us on [email protected]. For information on who to contact at each site in the UK call +44 (0)203 911 4385, in the US call 884 991 0504 and in Spain call 8000 999 08.

For more information on the FELIX study click here. We suggest that you discuss this information with your doctor (healthcare provider) to understand the available options open to you.

Additional information on the FELIX study can also be found on the Cancer Research UK website: FELIX study.